
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops prod... Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.375 | -23.2919254658 | 1.61 | 1.99 | 1.13 | 192939 | 1.44664325 | CS |
4 | -0.465 | -27.3529411765 | 1.7 | 2.09 | 1.13 | 249697 | 1.71242451 | CS |
12 | -2.455 | -66.5311653117 | 3.69 | 3.95 | 1.13 | 137009 | 1.91104904 | CS |
26 | -1.535 | -55.4151624549 | 2.77 | 5.95 | 1.13 | 89428 | 2.5573599 | CS |
52 | -3.095 | -71.4780600462 | 4.33 | 5.99 | 1.13 | 55733 | 2.91271188 | CS |
156 | -2.965 | -70.5952380952 | 4.2 | 9.6799 | 0.6706 | 344589 | 3.90972303 | CS |
260 | -13.565 | -91.6554054054 | 14.8 | 37.7 | 0.6706 | 588625 | 15.40082892 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions